On August 1, 2023 Alligator Bioscience AB (publ) ("Alligator" or the "Company") reported that the exercise period for warrants series TO 6 ended on 31 August 2023 (Press release, Alligator Bioscience, SEP 1, 2023, View Source [SID1234634828]). A total of 275,027,774 warrants were exercised for the subscription of 34,378,471 new ordinary shares, corresponding to a utilization rate of approximately 68 percent.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eight (8) warrants of series TO 6 entitled the holder to subscribe for one (1) new ordinary share in the Company at a subscription price of SEK 0.40 per share. A total of 275,027,774 warrants were exercised, corresponding to approximately 68 percent of all warrants of series TO 6, for the subscription of a total of 34,378,471 ordinary shares. Through the exercised warrants, Alligator receives approximately SEK 13.8 million before issue costs.

Increase in number of shares and share capital

Through the warrant exercise, the number of shares in Alligator increases by 34,378,471 ordinary shares, from a total of 624,525,669 to 658,904,140 shares, of which 657,954,290 are ordinary shares and 949,850 are series C shares. The share capital increases by SEK 2,200,222.144 to SEK 42,169,864.960. For existing shareholders who have not exercised any warrants, the dilution amounts to approximately 5.2 percent based on the number of shares in Alligator after the exercise of warrants. The total number of votes in the Company after the exercise of the warrants amounts to 658,049,275.

Delivery of subscribed shares

Subscribers of new shares through the exercise of warrants will receive interim shares (Sw. interimsaktier, IA) pending registration of the new shares with the Swedish Companies Registration Office (Sw. Bolagsverket). The conversion of interim shares into ordinary shares is estimated to take place around week 37 and the new ordinary shares will thereafter be admitted to trading on Nasdaq Stockholm.

Advisers
DNB Markets, a part of DNB Bank ASA, Sweden Branch and Redeye AB act as Joint Global Coordinators in connection with the Rights Issue. Setterwalls Advokatbyrå AB acts as legal adviser and Aktieinvest FK AB acts as the issuing agent in connection with the Rights Issue.

On September 1, 2023 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that the Phase III ALINA study evaluating its anti-cancer agent/ALK inhibitor Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis (Press release, Chugai, SEP 1, 2023, View Source;category= [SID1234634809]). Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Alecensa is the first ALK inhibitor to demonstrate a reduction in the risk of disease recurrence or death for people with early-stage ALK-positive NSCLC in a Phase III trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Overall survival (OS) data were immature at the time of this analysis. No unexpected safety findings were observed. Results from the ALINA study will be presented at an upcoming medical meeting and submitted to health authorities globally, including Japan, Europe, and the U.S..

"We are excited to see that Alecensa, widely used as a first-line treatment for ALK-positive advanced NSCLC, has demonstrated a reduction in the risk of disease recurrence or death in patients with early-stage NSCLC" said Dr. Osamu Okuda, Chugai’s President and CEO. "There are currently no ALK inhibitors approved in the adjuvant setting for NSCLC, despite the importance of preventing disease recurrence in order to bring a greater number of patients with early-stage NSCLC the potential for cure. We will closely collaborate with Roche towards submitting this data to regulatory authorities in Japan and other countries so that this drug can be used as soon as possible for patients who need it."

Today, about half of all people with early lung cancer (45-76%, depending on disease stage) still experience a cancer recurrence following surgery, despite adjuvant chemotherapy.1 Recent treatment innovations, including immunotherapies, have improved the outlook for some patients with early-stage NSCLC; however, there are no approved ALK-inhibitors for early-stage ALK-positive disease.2 Approximately five percent of people with NSCLC are ALK-positive.3 ALK-positive NSCLC is often found in younger people – usually 55 and under – who have a light or non-smoking history.4,5 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommend biomarker testing of resected surgical tissue or biopsy for ALK rearrangements in patients with stage IB to IIIA and IIIB NSCLC, in addition to in the advanced setting.

About the ALINA study
The ALINA study [NCT03456076] is a phase III, randomised, active-controlled, multicentre, open-label study evaluating the efficacy and safety of adjuvant Alecensa (alectinib) compared with platinum-based chemotherapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The study includes 257 patients who were randomly assigned to either the investigational or control treatment arm. The primary endpoint is disease-free survival (DFS). Secondary outcome measures include overall survival (OS) and percentage of patients with adverse events.

About Alecensa
Alecensa is a highly selective, central nervous system-active, oral medicine created at Chugai, a member of the Roche Group, Kamakura Research Laboratories for people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is now approved in over 100 countries as an initial (first-line) treatment for ALK-positive, metastatic NSCLC, including in the United States, Europe, Japan and China.

About lung cancer
Lung cancer is one of the leading causes of cancer death globally.6 Each year 1.8 million people die as a result of the disease; this translates into more than 4,900 deaths worldwide every day.6 Lung cancer can be broadly divided into two major types: non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC is the most prevalent type, accounting for around 85% of all cases.7 Today, about half of all people with early lung cancer (45-76%, depending on disease stage) still experience a cancer recurrence following surgery, despite adjuvant chemotherapy.1 Treating lung cancer early, before it has spread, may help prevent the disease from returning and provide people with the best opportunity for a cure.